---

---

tags : Pharm-country    exchanges : Nyse   

save search

---

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M |

Health Technology

| -2.17% | O: -1.08% H: 1.09% C: -0.55%
rtu first

---

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -1.22% | O: 0.11% H: 0.38% C: -0.04%
meeting

---

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
RLYB | News | $1.75 4.79% 4.57% 310K |

| 6.67% | O: -3.03% H: 4.38% C: 1.87%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -2.27% | O: 0.21% H: 0.0% C: 0.0%
risk solutions for collaboration

---

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -2.09% | O: 0.73% H: 2.49% C: 0.11%
abrysvo disease positive risk for rsv results study

---

Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release
Published: 2024-04-05 (Crawled : 13:30) - biospace.com/
COR | $239.13 0.77% 0.0% 1.4M |

Finance

| -1.2% | O: 0.28% H: 0.45% C: 0.21%
for

---

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
Published: 2024-04-04 (Crawled : 19:00) - biospace.com/
BDX | $234.12 0.42% 0.0% 1.3M |

Health Technology

| -3.89% | O: 0.61% H: 0.0% C: 0.0%
ANGO | $6.26 2.29% 2.24% 480K |

Health Technology

| -0.79% | O: 1.43% H: 12.5% C: 0.0%
year financial

---

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M |

Health Technology

| -10.71% | O: 0.0% H: 0.33% C: -2.64%
fda approval

---

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
Published: 2024-03-25 (Crawled : 13:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -5.78% | O: 0.29% H: 1.27% C: 0.33%
cardiovascular cardiology

---

Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -5.54% | O: -0.33% H: 1.02% C: 0.48%
opdivo treatment trial advanced plus

---

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Published: 2024-03-18 (Crawled : 13:30) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -6.52% | O: 0.46% H: 0.23% C: -1.88%
acquisition

---

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Published: 2024-03-15 (Crawled : 21:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -8.01% | O: -1.58% H: 0.0% C: 0.0%
LEGN | $46.14 -2.08% -2.12% 1.2M |

Health Technology

| -30.13% | O: -0.27% H: 4.91% C: -2.9%
carvykti fda treatment

---

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published: 2024-03-15 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M |

Health Technology

| 4.37% | O: -0.56% H: 1.75% C: 1.4%
keytruda cancer alone advanced plus

---

Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M |

Health Technology

| 1.85% | O: 0.93% H: 0.0% C: -1.51%
merck acquisition

---

Teladoc Health to Participate in Upcoming Investor Conference - March 8, 2024
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
TDOC S | $12.98 -1.52% 0.08% 5.3M |

Health Services

| -15.44% | O: 1.37% H: 1.74% C: -0.9%
conference health

---

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - March 5, 2024
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| 0.42% | O: -0.08% H: 2.13% C: 0.81%
conference

---

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -6.34% | O: -0.32% H: 0.0% C: -1.77%
TNXP | $0.159 1.27% 1.26% 1.1M |

Health Technology

| -50.31% | O: 4.32% H: 7.17% C: 2.5%
drug fibromyalgia study

---

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Published: 2024-02-26 (Crawled : 14:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -5.28% | O: -0.19% H: 0.23% C: -2.02%
acquisition platform

---

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -7.82% | O: 0.28% H: 0.0% C: 0.0%
LEGN | $46.14 -2.08% -2.12% 1.2M |

Health Technology

| -25.16% | O: 2.07% H: 5.02% C: 4.92%
carvykti chmp biotech positive treatment therapy

---

Zoetis to Participate in the Bank of America Securities 2024 Animal Health Summit
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
ZTS | News | $146.5 -4.32% 0.0% 6.2M |

Health Technology

| -21.47% | O: 0.06% H: 1.18% C: 0.92%
america health animal

---

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Published: 2024-02-20 (Crawled : 23:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -5.56% | O: 0.12% H: 0.0% C: 0.0%
tecvayli fda approved treatment

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---